Biotech Spotlight: Page 2
-
Q&A // Biotech Spotlight
Evommune’s unique method of drug discovery is more than skin deep
The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.
By Michael Gibney • Nov. 29, 2022 -
Q&A // Biotech Spotlight
The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology
Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.
By Karissa Waddick • Oct. 27, 2022 -
Q&A // Biotech Spotlight
Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets
CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.
By Karissa Waddick • Oct. 11, 2022 -
Q&A // Biotech Spotlight
Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform
As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.
By Kim Ribbink • June 30, 2022 -
Q&A // Biotech Spotlight
Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience
An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.
By Kim Ribbink • June 16, 2022 -
Q&A // Biotech Spotlight
Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
By Michael Gibney • May 17, 2022 -
Q&A // Biotech Spotlight
Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
By Taren Grom • May 9, 2022 -
Q&A // Biotech Spotlight
How OliX Pharmaceuticals is riding the RNAi wave
While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.
By Karissa Waddick , Taren Grom • April 25, 2022
To find more content, use the "Topics" in the menu above.